Remove Drug Development Remove Leadership Remove Medical Technology Remove Pharmaceuticals
article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

Seamless Therapeutics has a first-mover position with its innovative platform capable of modifying the long held standard recombination technology into a universal gene editing tool with unprecedented specificity. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.